A polymorphism at the miR-502 binding site in the 3' untranslated region of the SET8 gene is associated with the risk of epithelial ovarian cancer

Cancer Genetics

Volumn 205, Issue 7-8, 2012, Pages 373-376

  Wang, Cuiju ^a   Guo, Zhanjun ^a   Wu, Chensi ^a   Li, Yan ^a   Kang, Shan ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Cancer risk; EOC; MicroRNA; SET8

Indexed keywords

MESSENGER RNA; MICRORNA; MICRORNA 502; TUMOR PROTEIN; UNCLASSIFIED DRUG; HISTONE LYSINE METHYLTRANSFERASE; MIRN502 MICRORNA, HUMAN; PRIMER DNA; SETD8 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ADULT; ARTICLE; BINDING SITE; CANCER RISK; CANCER STAGING; CARCINOGENESIS; CASE CONTROL STUDY; CHINESE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENE LOCATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MOLECULAR PATHOLOGY; OVARY CARCINOMA; PRIORITY JOURNAL; RISK ASSESSMENT; SET8 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR GENE; GENETIC PREDISPOSITION; GENETICS; NEOPLASM; NUCLEOTIDE SEQUENCE; OVARY TUMOR; POLYMERASE CHAIN REACTION;

3' UNTRANSLATED REGIONS; BASE SEQUENCE; BINDING SITES; DNA PRIMERS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; MICRORNAS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84867165353     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2012.04.010     Document Type: Article

References (26)

1. Ahmed F.Y., Wiltshaw E., A'Hern R.P., et al. Natural history and prognosis of untreated stage I epithelial ovarian carcinoma. J Clin Oncol 1996, 14:2968-2975.
2. Li Y., Jia J.-H., Kang S., et al. The functional polymorphisms on promoter region of matrix metalloproteinase-12, -13 genes may alter the risk of epithelial ovarian carcinoma in Chinese. Int J Gynecol Cancer 2009, 19:129-133.
3. Fehrmann R.S., Li X.Y., van der Zee A.G., et al. Profiling studies in ovarian cancer: a review. Oncologist 2007, 12:960-966.
4. Munksgaard P.S., Blaakaer J. The association between endometriosis and gynecological cancers and breast cancer: a review of epidemiological data. Gynecol Oncol 2011, 123:157-163.
5. Gram I.T., Lukanova A., Brill I., et al. Cigarette smoking and risk of histological subtypes of epithelial ovarian cancer in the EPIC cohort study. Int J Cancer 2012, 130:2204-2210.
6. Kang S., Wang D.-J., Li W.-S., et al. Association of p73 and MDM2 polymorphisms with the risk of epithelial ovarian cancer in Chinese women. Int J Gynecol Cancer 2009, 19:572-577.
7. Li Y., Liang J., Kang S., et al. E-cadherin gene polymorphisms and haplotype associated with the occurrence of epithelial ovarian cancer in Chinese. Gynecologic Oncology 2008, 108:409-414.
8. Yan L., Na W., Shan K., et al. p16(CDKN2) gene polymorphism: association with histologic subtypes of epithelial ovarian cancer in China. Int J Gynecol Cancer 2007, 18:30-35.
9. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
10. Ambros V. The functions of animal microRNAs. Nature 2004, 431:350-355.
11. Lewis B.P., Burge C.B., Bartel D.P. Conserved seed pairing, often flanked by adenosines, indicateds that thousands of human genes are microRNA targets. Cell 2005, 120:15-20.
12. Zeng Y., Yi R., Cullen B.R. MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms. Proc Natl Acad Sci U S A 2003, 100:9779-9784.
13. Zeng Y., Wagner E.J., Cullen B.R. Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells. Mol Cell 2002, 9:1327-1333.
14. Chin L.J., Ratner E., Leng S., et al. A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. Cancer Res 2008, 68:8535-8540.
15. Brendle A., Lei H., Brandt A., et al. Polymorphisms in predicted microRNA-binding sites in integrin genes and breast cancer: ITGB4 as prognostic marker. Carcinogenesis 2008, 29:1394-1399.
16. Yu Z., Li Z., Jolicoeur N., et al. Aberrant allele frequencies of the SNPs located in microRNA target sites are potentially associated with human cancers. Nucleic Acids Research 2007, 35:4535-4541.
17. Landi D., Gemignani F., Naccarati A., et al. Polymorphisms within micro-RNA-binding sites and risk of sporadic colorectal cancer. Carcinogenesis 2008, 29:579-584.
18. Saunders M.A., Liang H., Li W- H. Human polymorphism at microRNA and microRNA target sites. Proc Natl Acad Sci U S A 2007, 9:3300-3305.
19. Gao Y., He Y., Ding J., et al. An insertion/deletion polymorphism at miRNA-122-binding site in the interleukin-1alpha 3' untranslated region confers risk for hepatocellular carcinoma. Carcinogenesis 2009, 30:2064-2069.
20. Fang J., Feng Q., Ketel C.S., et al. Purification and functional characterization of SET8, a nucleosomal histone H4-lysine 20-specific methyltransferase. Curr Biol 2002, 12:1086-1099.
21. Nishioka K., Rice J.C., Sarma K., et al. PR-Set7 is a nucleosome-specific methyltransferase that modifies lysine 20 of histone H4 and is associated with silent chromatin. Mol Cell 2002, 9:1201-1213.
22. Wu S., Wang W., Kong X., et al. Dynamic regulation of the PR-Set7 histone methyltransferase is required for normal cell cycle progression. Genes Dev 2010, 24:2531-2542.
23. Song F., Zheng H., Liu B., et al. An miR-502-binding site single-nucleotide polymorphism in the 3'-untranslated region of the SET8 gene is associated with early age of breast cancer onset. Clin Cancer Res 2009, 19:6292-6300.
24. Shi X., Kachirskaia I., Yamaguchi H., et al. Modulation of p53 function by SET8-mediated methylation at lysine 382. Mol Cell 2007, 27:636-646.
25. Guo Z., Wu C., Wang X., et al. A polymorphism at the miR-502 biding site in the 3'untranslated region of the histone methyltransferase SET8 is associated with hepatocellular carcinoma outcome. Int J Cancer 2011 Nov 18, [Epub ahead of print ].
26. Merritt W.M., Lin Y.G., Han L.Y., et al. Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med 2008, 359:2641-2650.